Key Sessions
Niklas Engler
Next Generation Process Development and Manufacturing for Cell and Gene Therapies - Improving Efficiencies and Reducing Cost of Goods
F. Hoffmann-La Roche
Thomas Kelly
When will we have a clone? An industry perspective on the typical CLD timeline
Johnson & Johnson Innovative Medicine
Garima Thakur
Intensification of Downstream Manufacturing of Recombinant Adeno-Viral Vectors using Continuous Processing
Regeneron Pharmaceuticals
Marinna Madrid
An autonomous Biomanufacturing platform to scale production of autologous iPSC-derived cell therapies
Cellino